Table 1 Clinical profile of patients enrolled in the study
Rapid progressors | Stable patients | |
|---|---|---|
Number of patients | 170 | 244 |
Age mean, years | 55.6 | 65.2 |
Age median (with interquartile ranges), years | 54.7 (46.1–66.0) | 66.9 (56.7–76.5) |
Male gender, n (%) | 92 (54) | 167 (68) |
White, n (%) | 159 (94) | 238 (98) |
Systolic blood pressure median (with IQR), mmHg | 142 (130–152) | 136 (122–147) |
Diastolic blood pressure median (with IQR), mmHg | 80 (71–88) | 73 (66–81) |
Hypertension, n (%) | 162 (95) | 228 (93) |
Diabetes, n (%) | 49 (29) | 82 (34) |
Smoking, n (%) | 105 (62) | 153 (63) |
Myocardial infarction, n (%) | 8 (5) | 22 (9) |
Heart failure, n (%) | 7 (4) | 12 (5) |
Stroke, n (%) | 7 (4) | 8 (3) |
Peripheral vascular disease, n (%) | 8 (5) | 12 (5) |
ACEi/ARB, n (%) | 129 (76) | 163 (67) |
Statin, n (%) | 101 (59) | 165 (68) |
Years follow-up median (with IQR) | 4.8 (3.6–6.3) | 6.5 (5.0–9.1) |
Primary renal disease | ||
Diabetic nephropathy, n (%) | 37 (22) | 46 (19) |
ADPKD, n (%) | 43 (25) | 4 (2) |
Hypertensive nephropathy, n (%) | 15 (9) | 24 (10) |
Glomerulonephritis, n (%) | 23 (14) | 42 (17) |
Other, n (%) | 39 (23) | 89 (36) |
Unknown, n (%) | 13 (8) | 39 (16) |
Laboratory results—median (with IQR) | ||
eGFR (ml/min/1.73 m2) | 32 (23–41) | 25 (18–33) |
ΔGFR (ml/min/1.73 m2/year) | − 4.75 (− 6.33 to − 3.70) | 0.09 (− 0.24 to + 0.50) |
eGFR results per patient, n | 26 (17–37) | 24 (16–40) |
Bicarbonate (mmol/l) | 22.0 (20.1–24.0) | 22.8 (20.8–24.7) |
Haemoglobin (g/l) | 121 (113–131) | 127 (117–137) |
Calcium (mmol/l) | 2.29 (2.19–2.38) | 2.28 (2.20–2.36) |
Phosphate (mmol/l) | 1.14 (1.01–1.27) | 1.06 (0.93–1.21) |
Albumin (g/l) | 42 (40–45) | 44 (42–46) |
uCPR (g/mol) | 85 (22–294) | 18 (9–38) |
Outcomes | ||
ESRD, n (%) | 111 (65) | 24 (10) |
Death prior to ESRD, n (%) | 18 (11) | 66 (27) |